Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer’s disease

Bibliography

• Hundt C, Peyrin JM, Haik S, et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J 2001;20(21):5876-86
   PubMed Web of Science ®Google Scholar
• Landowski TH, Dratz EA, Starkey JR. Studies of the structure of the metastasis-associated 67 kDa laminin binding protein: fatty acid acylation and evidence supporting dimerization of the 32 kDa gene product to form the mature protein. Biochemistry 1995;34(35):11276-87
   PubMed Web of Science ®Google Scholar
• Rao NC, Barsky SH, Terranova VP, et al. Isolation of a tumor cell laminin receptor. Biochem Biophys Res Commun 1983;111(3):804-8
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Kaneda Y, Sato M, et al. LBP-p40 binds DNA tightly through associations with histones H2A, H2B, and H4. Biochem Biophys Res Commun 1998;253(2):277-82
   PubMed Web of Science ®Google Scholar
• Ford CL, Randal-Whitis L, Ellis SR. Yeast proteins related to the p40/laminin receptor precursor are required for 20S ribosomal RNA processing and the maturation of 40S ribosomal subunits. Cancer Res 1999;59(3):704-10
   PubMedGoogle Scholar
• Mbazima V, Da Costa Dias B, Omar A, et al. Interactions between PrPc and other ligands with the 37-kDa/67-kDa laminin receptor. Front Biosci 2010;15:1150-63
   PubMed Web of Science ®Google Scholar
• Da Costa Dias B, Jovanovic K, Gonsalves D, et al. The 37kDa/67kDa Laminin Receptor acts as a receptor for Ab42 internalization. Sci Rep 2014;4:5556
   PubMedGoogle Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2012;64:206-12
   Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002;54(5):631-51
   PubMed Web of Science ®Google Scholar
• Abou-Jawde R, Choueiri T, Alemany C, et al. An overview of targeted treatments in cancer. Clin Ther 2003;25(8):2121-37
   PubMed Web of Science ®Google Scholar
• Reynolds AR, Moein Moghimi S, Hodivala-Dilke K. Nanoparticle-mediated gene delivery to tumour neovasculature. Trends Mol Med 2003;9(1):2-4
   PubMed Web of Science ®Google Scholar
• Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296(5577):2404-7
   PubMed Web of Science ®Google Scholar
• Ogris M, Walker G, Blessing T, et al. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Release 2003;91(1-2):173-81
   PubMed Web of Science ®Google Scholar
• Rao CN, Castronovo V, Schmitt MC, et al. Evidence for a precursor of the high-affinity metastasis-associated murine laminin receptor. Biochemistry 1989;28(18):7476-86
   PubMed Web of Science ®Google Scholar
• Moodley K, Weiss SF. Downregulation of the non-integrin laminin receptor reduces cellular viability by inducing apoptosis in lung and cervical cancer cells. PLoS One 2013;8(3):e57409
   PubMed Web of Science ®Google Scholar
• Turpeenniemi-Hujanen T, Thorgeirsson UP, Rao CN, et al. Laminin increases the release of type IV collagenase from malignant cells. J Biol Chem 1986;261(4):1883-9
   PubMedGoogle Scholar
• Ardini E, Sporchia B, Pollegioni L, et al. Identification of a novel function for 67-kDa laminin receptor: increase in laminin degradation rate and release of motility fragments. Cancer Res 2002;62(5):1321-5
   PubMedGoogle Scholar
• Nadji M, Nassiri M, Fresno M, et al. Laminin receptor in lymph node negative breast carcinoma. Cancer 1999;85(2):432-6
   PubMedGoogle Scholar
• Sanjuan X, Fernandez PL, Miquel R, et al. Overexpression of the 67-kD laminin receptor correlates with tumour progression in human colorectal carcinoma. J Pathol 1996;179(4):376-80
   PubMedGoogle Scholar
• al-Saleh W, Delvenne P, van den Brule FA, et al. Expression of the 67 KD laminin receptor in human cervical preneoplastic and neoplastic squamous epithelial lesions: an immunohistochemical study. J Pathol 1997;181(3):287-93
   PubMedGoogle Scholar
• Fontanini G, Vignati S, Chine S, et al. 67-Kilodalton laminin receptor expression correlates with worse prognostic indicators in non-small cell lung carcinomas. Clin Cancer Res 1997;3(2):227-31
   PubMedGoogle Scholar
• van den Brule FA, Berchuck A, Bast RC, et al. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 1994;30A(8):1096-9
   PubMedGoogle Scholar
• Montuori N, Selleri C, Risitano AM, et al. Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation. Clin Cancer Res 1999;5(6):1465-72
   PubMedGoogle Scholar
• Waltregny D, de Leval L, Menard S, et al. Independent prognostic value of the 67-kd laminin receptor in human prostate cancer. J Natl Cancer Inst 1997;89(16):1224-7
   PubMedGoogle Scholar
• van den Brule FA, Buicu C, Berchuck A, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 1996;27(11):1185-91
   PubMed Web of Science ®Google Scholar
• de Manzoni G, Guglielmi A, Verlato G, et al. Prognostic significance of 67-kDa laminin receptor expression in advanced gastric cancer. Oncology 1998;55(5):456-60
   PubMedGoogle Scholar
• Khusal R, Da Costa Dias B, Moodley K, et al. In vitro inhibition of angiogenesis by antibodies directed against the 37kDa/67kDa laminin receptor. PLoS One 2013;8(3):e58888
   PubMed Web of Science ®Google Scholar
• Fidler IJ. The pathogenesis of cancer metastasis: the ’seed and soil’ hypothesis revisited. Nat Rev Cancer 2003;3(6):453-8
   PubMed Web of Science ®Google Scholar
• Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127(4):679-95
   PubMed Web of Science ®Google Scholar
• Weinberg RA. Leaving home early: reexamination of the canonical models of tumor progression. Cancer Cell 2008;14(4):283-4
   PubMedGoogle Scholar
• Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14(6):818-29
   PubMed Web of Science ®Google Scholar
• Zijlstra A, Lewis J, Degryse B, et al. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 2008;13(3):221-34
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9(4):274-84
   PubMed Web of Science ®Google Scholar
• Knackmuss S, Rey C, Rottgen P, et al. inventors; Weiss SFT, Little M, assignee. Single chain antibody acting against 37kDa/67kDa laminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and uses thereof. WO035580 A1; 2005
   Google Scholar
• Little M, Reusch U, Kipriyanov S, et al. inventors; Affimed Therapuetics AG, assignee. The Use of an antibody against the laminin receptor precursor for the treatment or diagnosis of several cancer types patent. WO105954A2; 2006
   Google Scholar
• Findlay HP, Hahn SE, McConkey F, et al. inventors; F. Hoffman-La Roche, assignee; Cancerous disease modifying antibodies. WO007000A1 2010
   Google Scholar
• Berman DM, He X, Matsui W, et al. inventors. 67lr antibodies and their uses in the treatment of cancer. WO115601A1; 2008
   Google Scholar
• Khumalo T, Reusch U, Knackmuss S, et al. Adhesion and invasion of breast and oesophageal cancer cells are impeded by anti-LRP/LR-specific antibody IgG1-iS18. PLoS One 2013;8(6):e66297
   PubMed Web of Science ®Google Scholar
• Omar A, Reusch U, Knackmuss S, et al. Anti-LRP/LR-specific antibody IgG1-iS18 significantly reduces adhesion and invasion of metastatic lung, cervix, colon and prostate cancer cells. J Mol Biol 2012;419(1-2):102-9
   PubMedGoogle Scholar
• Chetty C, Khumalo T, Da Costa Dias B, et al. Anti-LRP/LR specific antibody IgG1-iS18 impedes adhesion and invasion of liver cancer cells. PLoS One 2014;9(5):e96268
   PubMed Web of Science ®Google Scholar
• Zuber C, Knackmuss S, Zemora G, et al. Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37-kDa/67-kDa laminin receptor. J Mol Biol 2008;378(3):530-9
   PubMed Web of Science ®Google Scholar
• Wang Y, Dong H, Xu M, et al. 37-kDa laminin receptor precursor promotes lung adenocarcinoma cell invasion and metastasis by epithelial-to-mesenchymal transition. Cancer Gene Ther 2014;21(4):150-7
   PubMedGoogle Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52
   PubMed Web of Science ®Google Scholar
• Weiss SFT, Jovanovic K, Gonsalves D, et al. inventors; University of the Witwatersrand, assignee. Compounds for use in the treatment of Alzheimer’s Disease. WO042053A2; 2013
   Google Scholar
• Dixelius J, Jakobsson L, Genersch E, et al. Laminin-1 promotes angiogenesis in synergy with fibroblast growth factor by distinct regulation of the gene and protein expression profile in endothelial cells. J Biol Chem 2004;279(22):23766-72
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17(11):1359-70
   PubMed Web of Science ®Google Scholar
• Tanaka M, Narumi K, Isemura M, et al. Expression of the 37-kDa laminin binding protein in murine lung tumor cell correlates with tumor angiogenesis. Cancer Lett 2000;153(1-2):161-8
   PubMedGoogle Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18(1):4-25
   PubMed Web of Science ®Google Scholar
• Simon-Assmann P, Orend G, Mammadova-Bach E, et al. Role of laminins in physiological and pathological angiogenesis. Int J Dev Biol 2011;55(4-5):455-65
   PubMed Web of Science ®Google Scholar
• Selleri C, Ragno P, Ricci P, et al. The metastasis-associated 67-kDa laminin receptor is involved in G-CSF-induced hematopoietic stem cell mobilization. Blood 2006;108(7):2476-84
   PubMed Web of Science ®Google Scholar
• Bernard A, Gao-Li J, Franco CA, et al. Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. J Biol Chem 2009;284(16):10480-90
   PubMed Web of Science ®Google Scholar
• Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011;30:87
   PubMed Web of Science ®Google Scholar
• Kumar V, Abbas AK, Fausto N, et al. Robins and Cotran: pathologic basis of disease. 8th edition. Saunders Elsevier; Philadelphia: 2010
   Google Scholar
• Hengartner MO. The biochemistry of apoptosis. Nature 2000;407(6805):770-6
   PubMed Web of Science ®Google Scholar
• Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21(3):485-95
   PubMed Web of Science ®Google Scholar
• Susantad T, Smith DR. siRNA-mediated silencing of the 37/67-kDa high affinity laminin receptor in Hep3B cells induces apoptosis. Cell Mol Biol Lett 2008;13(3):452-64
   PubMedGoogle Scholar
• Sun L, Liu L, Liu X, et al. MGr1-Ag/37LRP induces cell adhesion-mediated drug resistance through FAK/PI3K and MAPK pathway in gastric cancer. Cancer Sci 2014;105(6):651-9
   PubMed Web of Science ®Google Scholar
• Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43(2 Pt 1):405-13
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266(5193):2011-15
   PubMed Web of Science ®Google Scholar
• Letsolo BT, Rowson J, Baird DM. Fusion of short telomeres in human cells is characterized by extensive deletion and microhomology, and can result in complex rearrangements. Nucleic Acids Res 2010;38(6):1841-52
   PubMedGoogle Scholar
• Capper R, Britt-Compton B, Tankimanova M, et al. The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes Dev 2007;21(19):2495-508
   PubMedGoogle Scholar
• Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406(6796):641-5
   PubMedGoogle Scholar
• Zhu H, Belcher M, van der Harst P. Healthy aging and disease: role for telomere biology? Clin Sci (Lond) 2011;120(10):427-40
   PubMed Web of Science ®Google Scholar
• Hewitt G, Jurk D, Marques FD, et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat Commun 2012;3:708
   PubMed Web of Science ®Google Scholar
• Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011;11(3):161-76
   PubMed Web of Science ®Google Scholar
• Cong Y, Shay JW. Actions of human telomerase beyond telomeres. Cell Res 2008;18(7):725-32
   PubMed Web of Science ®Google Scholar
• Tomas-Loba A, Flores I, Fernandez-Marcos PJ, et al. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 2008;135(4):609-22
   PubMed Web of Science ®Google Scholar
• Lin TT, Letsolo BT, Jones RE, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood 2010;116(11):1899-907
   PubMedGoogle Scholar
• Cerone MA, Londono-Vallejo JA, Autexier C. Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol Cancer Ther 2006;5(7):1669-75
   PubMed Web of Science ®Google Scholar
• Boccardi V, Herbig U. Telomerase gene therapy: a novel approach to combat aging. EMBO Mol Med 2012;4(8):685-7
   PubMedGoogle Scholar
• Agrawal A, Dang S, Gabrani R. Recent patents on anti-telomerase cancer therapy. Recent Pat Anticancer Drug Discov 2012;7(1):102-17
   PubMedGoogle Scholar
• Grand CL, Han H, Munoz RM, et al. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 2002;1(8):565-73
   PubMed Web of Science ®Google Scholar
• Sekhri K. Telomeres and telomerase: understanding basic structure and potential new therapeutic strategies targeting it in the treatment of cancer. J Postgrad Med 2014;60(3):303-8
   PubMedGoogle Scholar
• Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2002;2(4):257-65
   PubMed Web of Science ®Google Scholar
• Nikles D, Vana K, Gauczynski S, et al. Subcellular localization of prion proteins and the 37 kDa/67 kDa laminin receptor fused to fluorescent proteins. Biochim Biophys Acta 2008;1782(5):335-40
   PubMedGoogle Scholar
• Santos JH, Meyer JN, Van Houten B. Mitochondrial localization of telomerase as a determinant for hydrogen peroxide-induced mitochondrial DNA damage and apoptosis. Hum Mol Genet 2006;15(11):1757-68
   PubMedGoogle Scholar
• Naidoo K, Letsolo B, Weiss SFT; inventors; University of the Witwatersrand, assignee. Modifying telomerase activity. South African Provisional Patent Application 2014/08860;2014
   Google Scholar
• Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res 2012;43(8):600-8
   PubMed Web of Science ®Google Scholar
• Selkoe D. The therapeutics of Alzheimer’s disease: where we stand and where we are heading. Ann Neurobiol 2013;74(3):328-36
   PubMedGoogle Scholar
• Choi SH, Kim YH, Hebisch M, et al. A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature 2014;515(7526):274-8
   PubMed Web of Science ®Google Scholar
• Pawar AP, Dubay KF, Zurdo J, et al. Prediction of “aggregation-prone” and “aggregation-susceptible” regions in proteins associated with neurodegenerative diseases. J Mol Biol 2005;350(2):379-92
   PubMedGoogle Scholar
• Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994;13(1):45-53
   PubMed Web of Science ®Google Scholar
• Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005;8(1):79-84
   PubMed Web of Science ®Google Scholar
• Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012;2(7):a006338
   PubMed Web of Science ®Google Scholar
• Linden R, Martins VR, Prado MA, et al. Physiology of the prion protein. Physiol Rev 2008;88(2):673-728
   PubMed Web of Science ®Google Scholar
• Harris DA, Huber MT, van Dijken P, et al. Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites. Biochemistry 1993;32(4):1009-16
   PubMedGoogle Scholar
• Westergard L, Christensen HM, Harris DA. The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta 2007;1772(6):629-44
   PubMed Web of Science ®Google Scholar
• Lauren J, Gimbel DA, Nygaard HB, et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009;457(7233):1128-32
   PubMed Web of Science ®Google Scholar
• Um JW, Nygaard HB, Heiss JK, et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012;15(9):1227-35
   PubMed Web of Science ®Google Scholar
• Zhou J, Liu B. Alzheimer’s disease and prion protein. Intractable Rare Dis Res 2013;2(2):35-44
   PubMedGoogle Scholar
• Rushworth JV, Griffiths HH, Watt NT, et al. Prion protein-mediated toxicity of amyloid-beta oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem 2013;288(13):8935-51
   PubMedGoogle Scholar
• Pflanzner T, Petsch B, Andre-Dohmen B, et al. Cellular prion protein participates in amyloid-beta transcytosis across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32(4):628-32
   PubMedGoogle Scholar
• Gauczynski S, Peyrin JM, Haik S, et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 2001;20(21):5863-75
   PubMed Web of Science ®Google Scholar
• Rieger R, Edenhofer F, Lasmezas CI, et al. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med 1997;3(12):1383-8
   PubMed Web of Science ®Google Scholar
• Omar A, Jovanovic K, Da Costa Dias B, et al. Patented biological approaches for the therapeutic modulation of the 37 kDa/67 kDa laminin receptor. Expert Opin Ther Pat 2011;21(1):35-53
   PubMed Web of Science ®Google Scholar
• Da Costa Dias B, Jovanovic K, Gonsalves D, et al. Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from Abeta42 induced cytotoxicity. Sci Rep 2013;3:2702
   PubMedGoogle Scholar
• Jovanovic K, Gonsalves D, Dias Bda C, et al. Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer’s disease. Sci Rep 2013;3:2699
   PubMed Web of Science ®Google Scholar
• Jovanovic K, Loos B, Da Costa Dias B, et al. High resolution imaging study of interactions between the 37 kDa/67 kDa laminin receptor and APP, beta-secretase and gamma-secretase in Alzheimer’s disease. PLoS One 2014;9(6):e100373
   Google Scholar
• Griffiths HH, Whitehouse IJ, Baybutt H, et al. Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. J Biol Chem 2011;286(38):33489-500
   PubMedGoogle Scholar
• Beckman M, Holsinger RM, Small DH. Heparin activates beta-secretase (BACE1) of Alzheimer’s disease and increases autocatalysis of the enzyme. Biochemistry 2006;45(21):6703-14
   PubMed Web of Science ®Google Scholar
• Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284(5415):770-6
   PubMed Web of Science ®Google Scholar
• Zuber C, Mitteregger G, Pace C, et al. Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice. Prion 2007;1(3):207-12
   PubMed Web of Science ®Google Scholar
• Vana K, Zuber C, Pflanz H, et al. LRP/LR as an alternative promising target in therapy of prion diseases, Alzheimer’s disease and cancer. Infect Disord Drug Targets 2009;9(1):69-80
   PubMedGoogle Scholar
• Zuber C, Knackmuss S, Rey C, et al. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 2008;45(1):144-51
   PubMed Web of Science ®Google Scholar
• Pflanz H, Vana K, Mitteregger G, et al. Microinjection of lentiviral vectors expressing small interfering RNAs directed against laminin receptor precursor mRNA prolongs the pre-clinical phase in scrapie-infected mice. J Gen Virol 2009;90(Pt 1):269-74
   PubMedGoogle Scholar
• Morgan D. Immunotherapy for Alzheimer’s disease. J Intern Med 2011;269(1):54-63
   PubMedGoogle Scholar
• Black R, Ekman L, Lieberburg I, et al. inventors; Wyeth, Elan Pharma International Limited, assignee. Immunotherapy regimes dependent on APOE Status. US20090155256. 2008
   Google Scholar
• Probst G, Xu YZ. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011). Expert Opin Ther Pat 2012;22(5):511-40
   PubMed Web of Science ®Google Scholar
• Orihuela CJ, Mahdavi J, Thornton J, et al. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Invest 2009;119(6):1638-46
   PubMedGoogle Scholar
• Kim KJ, Chung JW, Kim KS. 67-kDa laminin receptor promotes internalization of cytotoxic necrotizing factor 1-expressing Escherichia coli K1 into human brain microvascular endothelial cells. J Biol Chem 2005;280(2):1360-8
   PubMed Web of Science ®Google Scholar
• Favaloro B, Allocati N, Graziano V, et al. Role of apoptosis in disease. Aging (Albany NY) 2012;4(5):330-49
   PubMedGoogle Scholar